116 related articles for article (PubMed ID: 37659219)
1. Discovery of a potent, orally available tricyclic derivative as a novel BRD4 inhibitor for melanoma.
Horai Y; Suda N; Uchihashi S; Katakuse M; Shigeno T; Hirano T; Takahara J; Fujita T; Mukoyama Y; Haga Y
Bioorg Med Chem; 2023 Oct; 93():117461. PubMed ID: 37659219
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping.
Zhang Z; Gu L; Wang B; Huang W; Zhang Y; Ma Z; Zeng S; Shen Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):808-817. PubMed ID: 30879350
[TBL] [Abstract][Full Text] [Related]
3. A 7-methoxybicoumarin derivative selectively inhibits BRD4 BD2 for anti-melanoma therapy.
Yang GJ; Wang W; Lei PM; Leung CH; Ma DL
Int J Biol Macromol; 2020 Dec; 164():3204-3220. PubMed ID: 32860796
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and anticancer evaluation of ammosamide B with pyrroloquinoline derivatives as novel BRD4 inhibitors.
Li W; Zhang C; Zhang HE; Dong R; Liu JY; Wang CM; Wang M; Wang YW; Wang C; Zhang Y; Shi L; Xu Y; Sun LP
Bioorg Chem; 2022 Oct; 127():105917. PubMed ID: 35738217
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.
Liu Z; Chen H; Wang P; Li Y; Wold EA; Leonard PG; Joseph S; Brasier AR; Tian B; Zhou J
J Med Chem; 2020 May; 63(10):5242-5256. PubMed ID: 32255647
[TBL] [Abstract][Full Text] [Related]
7. Discovery and anti-tumor activity of 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one (CG13250), a potent, selective and orally bioavailable BET bromodomain inhibitor.
Chauhan J; Yoshioka M; Pogash S; Strovel JW; Fletcher S
Bioorg Med Chem Lett; 2023 Apr; 86():129220. PubMed ID: 36905966
[TBL] [Abstract][Full Text] [Related]
8. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors.
Xu Y; Zhang XJ; Li WB; Wang XR; Wang S; Qiao XP; Chen SW
Eur J Med Chem; 2020 Dec; 208():112780. PubMed ID: 32883643
[TBL] [Abstract][Full Text] [Related]
10. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
11. Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.
Pietrobono S; Gaudio E; Gagliardi S; Zitani M; Carrassa L; Migliorini F; Petricci E; Manetti F; Makukhin N; Bond AG; Paradise BD; Ciulli A; Fernandez-Zapico ME; Bertoni F; Stecca B
Oncogene; 2021 Jun; 40(22):3799-3814. PubMed ID: 33958721
[TBL] [Abstract][Full Text] [Related]
12. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.
Segura MF; Fontanals-Cirera B; Gaziel-Sovran A; Guijarro MV; Hanniford D; Zhang G; González-Gomez P; Morante M; Jubierre L; Zhang W; Darvishian F; Ohlmeyer M; Osman I; Zhou MM; Hernando E
Cancer Res; 2013 Oct; 73(20):6264-76. PubMed ID: 23950209
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of quinoxalinone derivatives as potent BRD4 inhibitors.
Xu KY; Wang XT; Cheng L; Cui QH; Shi JT; Zhang LW; Chen SW
Bioorg Med Chem; 2023 Jan; 78():117152. PubMed ID: 36599264
[TBL] [Abstract][Full Text] [Related]
14. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.
Nerlakanti N; Yao J; Nguyen DT; Patel AK; Eroshkin AM; Lawrence HR; Ayaz M; Kuenzi BM; Agarwal N; Chen Y; Gunawan S; Karim RM; Berndt N; Puskas J; Magliocco AM; Coppola D; Dhillon J; Zhang J; Shymalagovindarajan S; Rix U; Kim Y; Perera R; Lawrence NJ; Schonbrunn E; Mahajan K
Mol Cancer Ther; 2018 Dec; 17(12):2796-2810. PubMed ID: 30242092
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension.
Meloche J; Potus F; Vaillancourt M; Bourgeois A; Johnson I; Deschamps L; Chabot S; Ruffenach G; Henry S; Breuils-Bonnet S; Tremblay È; Nadeau V; Lambert C; Paradis R; Provencher S; Bonnet S
Circ Res; 2015 Aug; 117(6):525-35. PubMed ID: 26224795
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.
Feng Z; Chen A; Shi J; Zhou D; Shi W; Qiu Q; Liu X; Huang W; Li J; Qian H; Zhang W
Bioorg Chem; 2021 Jun; 111():104849. PubMed ID: 33798846
[TBL] [Abstract][Full Text] [Related]
17. Piecing the Fragments Together: Dynamical Insights into the Enhancement of BRD4-BD1 (BET Protein) Druggability in Cancer Chemotherapy Using Novel 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives.
Akawa OB; Soremekun OS; Olotu FA; Solima MES
Curr Pharm Biotechnol; 2022; 23(3):444-456. PubMed ID: 33749556
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
19. Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
Sato M; Kondo T; Kohno Y; Seto S
Bioorg Med Chem; 2021 Mar; 34():116015. PubMed ID: 33549905
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the Epigenetic Reader BRD4 Reduces SIRPα-Mediated Phagocytosis and Melanoma Invasion.
Scheeren FA; van Doorn R
J Invest Dermatol; 2021 Feb; 141(2):252-254. PubMed ID: 33504439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
